BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Lin A, Li Y, Ding W, Meng H, Luo P, Zhang J. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Front Cell Dev Biol 2020;8:608969. [PMID: 33363171 DOI: 10.3389/fcell.2020.608969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Yilmaz E, Ismaila N, Bauman JE, Dabney R, Gan G, Jordan R, Kaufman M, Kirtane K, McBride SM, Old MO, Rooper L, Saba NF, Sheth S, Subramaniam RM, Wise-Draper TM, Wong D, Mell LK. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. J Clin Oncol 2023;41:1132-46. [PMID: 36521102 DOI: 10.1200/JCO.22.02328] [Reference Citation Analysis]
2 Yao J, You Q, Zhang X, Zhang Y, Xu J, Zhao X, Li J, Wang X, Gong Z, Zhang D, Wang W. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients. Clin Genet 2023;103:200-8. [PMID: 36346122 DOI: 10.1111/cge.14260] [Reference Citation Analysis]
3 Bredel M, Kim H, Bonner JA. An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma. IJMS 2022;23:13497. [DOI: 10.3390/ijms232113497] [Reference Citation Analysis]
4 Mezi S, Pomati G, Zizzari IG, Di Filippo A, Cerbelli B, Cirillo A, Fiscon G, Amirhassankhani S, Valentini V, De Vincentiis M, Corsi A, Di Gioia C, Tombolini V, Della Rocca C, Polimeni A, Nuti M, Marchetti P, Botticelli A. Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile. Biomedicines 2022;10:2732. [DOI: 10.3390/biomedicines10112732] [Reference Citation Analysis]
5 Zhang N, Shen J, Gou L, Cao M, Ding W, Luo P, Zhang J. UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer. Bioengineered 2022;13:11577-92. [DOI: 10.1080/21655979.2022.2069328] [Reference Citation Analysis]
6 Cao J, Yang X, Chen S, Wang J, Fan X, Fu S, Yang L. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. Transl Oncol 2022;20:101375. [PMID: 35339028 DOI: 10.1016/j.tranon.2022.101375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ren X, Guo S, Guan X, Kang Y, Liu J, Yang X. Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy. Front Immunol 2022;13:790113. [DOI: 10.3389/fimmu.2022.790113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lin X, Deng J, Deng H, Yang Y, Sun N, Zhou M, Qin Y, Xie X, Li S, Zhong N, Song Y, Zhou C. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis. Front Immunol 2021;12:818492. [PMID: 35095920 DOI: 10.3389/fimmu.2021.818492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Feng C, Liu S, Shang Z. Identification and Validation of an EMT-Related LncRNA Signature for HNSCC to Predict Survival and Immune Landscapes. Front Cell Dev Biol 2022;9:798898. [DOI: 10.3389/fcell.2021.798898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Galli A, Colombo M, Prizio C, Carrara G, Lira Luce F, Paesano PL, Della Vecchia G, Giordano L, Bondi S, Tulli M, Di Santo D, Mirabile A, De Cobelli F, Bussi M. Skeletal Muscle Depletion and Major Postoperative Complications in Locally-Advanced Head and Neck Cancer: A Comparison between Ultrasound of Rectus Femoris Muscle and Neck Cross-Sectional Imaging. Cancers (Basel) 2022;14:347. [PMID: 35053512 DOI: 10.3390/cancers14020347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Guo Y, Pan WK, Wang ZW, Su WH, Xu K, Jia H, Chen J. Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis. Biomed Res Int 2021;2021:4532438. [PMID: 34917682 DOI: 10.1155/2021/4532438] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Peng YP, Wang R, Liu QD, Xu XW, Wei W, Huang XT, Peng XM, Liu ZG. Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Front Genet 2021;12:756506. [PMID: 34868231 DOI: 10.3389/fgene.2021.756506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xu X, Li R, Zhang L, Zhu G, Ren D, Wu L, Gong X. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma. Diagn Pathol 2021;16:110. [PMID: 34823553 DOI: 10.1186/s13000-021-01147-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Chen L, Zhou Q, Liu J, Zhang W. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:759565. [PMID: 34777372 DOI: 10.3389/fimmu.2021.759565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Burcher KM, Lantz JW, Gavrila E, Abreu A, Burcher JT, Faucheux AT, Xie A, Jackson C, Song AH, Hughes RT, Lycan T Jr, Bunch PM, Furdui CM, Topaloglu U, D'Agostino RB Jr, Zhang W, Porosnicu M. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5733. [PMID: 34830888 DOI: 10.3390/cancers13225733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Li L, Bai L, Lin H, Dong L, Zhang R, Cheng X, Liu Z, Ouyang Y, Ding K. Multiomics analysis of tumor mutational burden across cancer types. Comput Struct Biotechnol J 2021;19:5637-46. [PMID: 34745455 DOI: 10.1016/j.csbj.2021.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
17 Ma B, Jiang H, Luo Y, Liao T, Xu W, Wang X, Dong C, Ji Q, Wang Y. Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma. Front Immunol 2021;12:692079. [PMID: 34737735 DOI: 10.3389/fimmu.2021.692079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Sun Y, Yang Q, Shen J, Wei T, Shen W, Zhang N, Luo P, Zhang J. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Front Cell Dev Biol 2021;9:745859. [PMID: 34660603 DOI: 10.3389/fcell.2021.745859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lin A, Zhang H, Meng H, Deng Z, Gu T, Luo P, Zhang J. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol 2021;12:667875. [PMID: 34603277 DOI: 10.3389/fimmu.2021.667875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kumar G, South AP, Curry JM, Linnenbach A, Harshyne LA, Ertel A, Fortina P, Luginbuhl A. Multimodal genomic markers predict immunotherapy response in the head and neck squamous cell carcinoma.. [DOI: 10.1101/2021.03.30.437691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]